Medicant Healthcare

Okhla, delhi

Tacrolimus is used with other medications to prevent rejection of a kidney, heart, liver, or lung transplant. This medication belongs to a class of drugs known as immunosuppressants. It works by weakening your body’s defense system (immune system) to help your body accept the new organ as if it were your own.

Tacrolimus injection is used along with other medications to prevent rejection (attack of the transplanted organ by the transplant recipient’s immune system) in people who have received kidney, liver, or heart transplants. Tacrolimus injection should only be used by people who are unable to take tacrolimus by mouth. Tacrolimus injection is in a class of medications called immunosupressants. It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ.

The FDA approved the use of anastrozole (Arimidex) for the adjuvant treatment of hormone-receptor positive early breast cancer in postmenopausal women.

In September 2002, the FDA approved a supplemental new drug application (sNDA) for Arimidex under the provisions for accelerated approval, with further follow-up required for full approval. The supplemental approval was based on recurrence-free survival data from the Arimidex Tamoxifen Alone or in Combination (ATAC) trial with a median duration treatment of 31 months.

ARIMIDEX is an aromatase inhibitor indicated for:

• Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
• First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer
• Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

A drug used to treat prostate cancer, problems with the endometrium (lining of the uterus), and uterine fibroids (noncancerous growths of the uterus). It is also being studied in the treatment of other conditions and types of cancer. Leuprolide acetate keeps the body from making the hormones luteinizing hormone-releasing hormone (LHRH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone (a male hormone) in men, and the ovaries to stop making estradiol (a form of the hormone estrogen) in women. Leuprolide acetate may stop the growth of cancer cells that need testosterone to grow and stop the growth of endometrial tissue and uterine fibroids. It is a type of gonadotropin-releasing hormone (GnRH) agonist. Also called Eligard and Lupron Depot. US Brand Name(s): Eligard, Lupron Depot. FDA Approved Yes

Leuprorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer and breast cancer. It may also be used for estrogen-dependent conditions such as endometriosis or uterine fibroids. Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty, to perform chemical castration of violent sex offenders, or as part of transgender hormone therapy. It is given by injection into a muscle or under the skin.

Leuprolide acetate is approved for palliative treatment of: Prostate cancer that is advanced. Leuprolide acetate is also being studied in the treatment of other types of cancer.

A drug used alone or with other drugs to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose cancer has not already been treated or whose cancer has recurred (come back) or has gotten worse after treatment with anticancer drugs that included fluorouracil. It is also being studied in the treatment of other types of cancer. Camptosar blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog. Also called CPT 11 and irinotecan hydrochloride.

Irinotecan, sold under the brand name Camptosar among others, is a medication used to treat colon cancer, and small cell lung cancer.[4] For colon cancer it is used either alone or with fluorouracil. For small cell lung cancer it is used with cisplatin. It is given intravenously. Irinotecan was approved for medical use in the United States in 1996. It is on the World Health Organizations List of Essential Medicines.[6] It is made from the natural compound camptothecin which is found in the Chinese ornamental tree Camptotheca acuminata.

Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan. The regimen XELIRI consists of capecitabine and irinotecan.

It may also be used together with fluorouracil and folinic acid for pancreatic cancer following failure of initial treatment.

This medication is used alone or with other medications to treat moderate to severe rheumatoid arthritis in adults. It is also used to treat rheumatoid arthritis in children (such as polyarticular juvenile idiopathic arthritis-PJIA, systemic juvenile idiopathic arthritis-SJIA). It helps to reduce pain and swelling due to rheumatoid arthritis. Tocilizumab is used to treat giant cell arteritis. It helps to reduce swelling in your blood vessels so blood can flow more easily. This medication is also used to slow down the decrease in lung function in people with a certain type of lung disease (systemic sclerosis-associated interstitial lung disease SSc-ILD). Tocilizumab belongs to a class of drugs known as Interleukin-6 (IL-6) blockers. It works by blocking IL-6, a substance made by the body that causes swelling (inflammation).

Tocilizumab injection is used alone or in combination with other medications to relieve the symptoms of certain types of arthritis and other conditions including:

• rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults who have not been helped by other disease-modifying antirheumatic drugs (DMARDs),
• giant cell arteritis (a condition that causes swelling of blood vessels, especially in the scalp and head) in adults,
• systemic sclerosis-associated interstitial lung disease (SSc-ILD; also known as scleroderma-associated ILD: a lung disease that involves scarring of the lungs) in adults,
• polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children 2 years of age or older.
• systemic juvenile idiopathic arthritis (SJIA; a condition in children that causes inflammation in different areas of the body, causing fever, joint pain and swelling, loss of function, and delays in growth and development) in children 2 years of age or older,
• cytokine release syndrome (a severe and possibly life-threatening reaction) in adults and children 2 years of age or older after receiving certain immunotherapy infusions.

Tocilizumab injection is in a class of medications called interleukin-6 (IL-6) receptor inhibitors. It works by blocking the activity of interleukin-6, a substance in the body that causes inflammation.

This medication is used to treat plaque psoriasis and certain types of arthritis (psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis). Ixekizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-17A) that may cause inflammation and swelling.

Ixekizumab injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults and children 6 years of age and older whose psoriasis is too severe to be treated by topical medications alone. It is also used alone or in combination with certain medications such as methotrexate (Rasuvo, Trexall, others) to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults. Ixekizumab injection is also used to treat ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas, causing pain and joint damage) in adults. It is also used to treat active non-radiographic axial spondyloarthritis (a condition in which the body attacks the joints of the spine and other areas causing pain and signs of swelling, but without changes seen on x-ray) in adults, Ixekizumab injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes the symptoms of psoriasis.

Vinorelbine (NVB), sold under the brand name Navelbine among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer and non-small cell lung cancer. Vinorelbine was approved for medical use in the United States in 1994. It is on the World Health Organization’s List of Essential Medicines. Vinorelbine is approved for the treatment of non-small-cell lung cancer. It is used off-label for other cancers such as metastatic breast cancer. It is also active in rhabdomyosarcoma.

Vinorelbine is approved to treat metastatic non-small cell lung cancer (NSCLC). Lung cancer is the second most commonly diagnosedTrusted Source type of cancer worldwide (11.4 percent), after female breast cancer (11.7 percent). NSCLC is also the most common type of lung cancer.  

NAVELBINE is a vinca alkaloid indicated:

In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

As a single agent for first-line treatment of patients with metastatic NSCLC

DOSAGE AND ADMINISTRATION

• In combination with cisplatin: 25 to 30 mg/m2 as an intravenous injection or infusion once weekly
• Single agent: 30 mg/m2 as intravenously once a week
• Adjust dose in patients with decreased neutrophil counts or elevated serum total bilirubin

DOSAGE FORMS AND STRENGTHS

Injection: 10 mg/1 mL and 50 mg/5 mL in single-dose vial

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

Omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. Controlling symptoms of asthma helps you maintain your normal activities and cuts down on time lost from work or school. Omalizumab may also be used to treat nasal polyps or to treat hives from an unknown cause (chronic idiopathic urticaria-CIU).

This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, salbutamol) as prescribed.s, at least one of them for metastatic disease.

Omalizumab injection is used to decrease the number of asthma attacks (sudden episodes of wheezing, shortness of breath, and trouble breathing) in adults and children 6 years of age and older with allergic asthma (asthma caused by inhaling substances such as dander, pollen, and dust mites) whose symptoms are not controlled with inhaled steroids. It is also used to treat nasal polyps (swelling of the lining of the nose) in adults whose symptoms are not controlled with inhaled steroids. Omalizumab is also used to treat chronic hives without a known cause that cannot successfully be treated with antihistamine medications such as diphenhydramine (Benadryl), cetirizine (Zyrtec), hydroxyzine (Vistaril), and loratadine (Claritin) in adults and children 12 years of age and older. Omalizumab is not used to treat other forms of hives or allergic conditions. Omalizumab injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes the symptoms of allergic asthma, nasal polyps, and hives.

This medication is used to treat rheumatoid arthritis, a condition in which the body’s own defense system (immune system) attacks healthy tissue. This leads to swelling in the joints, which causes pain and makes it harder to move. Abatacept works by weakening your immune system. This effect helps to slow down joint damage and reduce joint pain and swelling so you can move better. This medication is also used to treat other types of arthritis (such as juvenile idiopathic arthritis, psoriatic arthritis).

Abatacept is used alone or in combination with other medications to reduce the pain, swelling, difficulty with daily activities, and joint damage caused by rheumatoid arthritis (a condition in which the body attacks its own joints causing pain, swelling, and loss of function) in adults who have not been helped by other medications. It is also used alone or in combination with methotrexate (Otrexup, Rasuvo, Reditrex, Trexall, Xatmep) to treat polyarticular juvenile idiopathic arthritis (PJIA; a type of childhood arthritis that affects five or more joints during the first six months of the condition, causing pain, swelling, and loss of function) in children 2 years of age or older. Abatacept is also used alone or in combination with other medications to treat psoriatic arthritis (condition that causes joint pain and swelling and scales on the skin) in adults. Abatacept is also used in combination with a calcineurin inhibitor (e.g., cyclosporine [Gengraf, Neoral, Sandimmune], tacrolimus [Astagraf, Prograf]) and methotrexate to prevent graft versus host disease (GVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow]) in adults and children 2 years of age and older. Abatacept is in a class of medications called selective costimulation modulators (immunomodulators). It works by blocking the activity of T-cells, a type of immune cell in the body that causes swelling and joint damage in people who have arthritis.

A drug that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to treat many different types of cancer, including cancers that express PD-L1. Atezolizumab is used alone or with other drugs to treat certain types of melanoma, hepatocellular carcinoma (a type of liver cancer), non-small cell lung cancer, small cell lung cancer, and urothelial cancer (a type of cancer in the bladder or urinary tract). It is also being studied in the treatment of other types of cancer. Atezolizumab may block PD-L1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Tecentriq. US Brand Name(s): Tecentriq. FDA Approved: Yes

In the European Union atezolizumab is indicated for the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma, and breast cancer.

In the United States, atezolizumab is indicated for the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and melanoma.

Atezolizumab is approved to treat:

• Hepatocellular carcinoma (a type of liver cancer) that is metastatic or cannot be removed by surgery. Atezolizumab is used with bevacizumab in patients who have not received systemic therapy.
• Melanoma that has a certain mutation in the BRAF gene. Atezolizumab is used with cobimetinib fumarate and vemurafenib in adults whose cancer is metastatic or cannot be removed by surgery.
• Non-small cell lung cancer.
• Small cell lung cancer. Atezolizumab is used with carboplatin and etoposide as the first treatment in adults with extensive-stage cancer.
• Urothelial cancer (a type of cancer in the bladder or urinary tract) that is metastatic or cannot be removed by surgery.

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that atezolizumab provides a clinical benefit in these patients.

Atezolizumab is also being studied in the treatment of other types of cancer.

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

The US Food and Drug Administration (FDA) has approved risankizumab-rzaa (Skyrizi, AbbVie) for a third indication — treatment of moderately to severely active Crohn’s disease in adults — making it the first specific anti-interleukin 23 (IL-23) monoclonal antibody indicated for Crohn’s disease.

This medication is used to treat plaque psoriasis and psoriatic arthritis. It is also used to treat a certain bowel condition called Crohn’s disease. Risankizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.

Risankizumab-rzaa injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. Risankizumab-rzaa is in a class of

A drug that binds to the protein PD-1 to help immune cells kill cancer cells better and is used to treat many different types of cancer. These include cancers that express the protein PD-L1 or that have certain mutations (changes) in genes involved in DNA repair. Nivolumab is used alone or with other drugs to treat certain types of esophageal cancer, gastroesophageal junction cancer, stomach cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), melanoma, hepatocellular carcinoma (a type of liver cancer), squamous cell carcinoma of the head and neck, classic Hodgkin lymphoma, urothelial carcinoma (a type of bladder or urinary tract cancer), and malignant pleural mesothelioma. It is also being studied in the treatment of other types of cancer. Nivolumab may block PD-1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Opdivo.

Nivolumab is approved to be used alone or with other drugs to treat:

• Classic Hodgkin lymphoma
• Colorectal cancer
• Esophageal cancer or gastroesophageal junction adenocarcinoma.
• Gastric (stomach) cancer, gastroesophageal junction adenocarcinoma, or esophageal cancer
• Malignant pleural mesothelioma.
• Melanoma
• Non-small cell lung cancer.
• Renal cell carcinoma
• Squamous cell carcinoma of the head and neck
• Urothelial carcinoma

Nivolumab was approved for medical use in the United States in 2014. It is on the World Health Organizations List of Essential Medicines. It is made using Chinese hamster ovary cells.

Nivolumab is the second FDA-approved systemic therapy for mesothelioma and is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

The combination of nivolumab with ipilimumab is used for the first-line treatment of adults with malignant pleural mesothelioma (MPM) that cannot be removed by surgery.

In April 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab, in combination with certain types of chemotherapy, for the initial treatment of people with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.

In May 2021, the U.S. FDA approved nivolumab for people with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.[8]

In August 2021, the U.S. FDA approved nivolumab for the adjuvant treatment of people with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.[16]

In May 2022, the U.S. FDA expanded the indication to include the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).

A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, gastroesophageal junction cancer, non-small cell lung cancer, prostate cancer, and squamous cell carcinoma of the head and neck. It is also being studied in the treatment of other types of cancer. Docetaxel stops cancer cells from growing and dividing and may kill them. It is a type of taxane. Also called Taxotere. US Brand Name(s): Taxotere. FDA Approved: Yes

Docetaxel is approved to be used alone or with other drugs to treat:

• Breast cancer that is locally advanced or has metastasized (spread to other parts of the body) and has not gotten better with other chemotherapy. It is also used with doxorubicin hydrochloride and cyclophosphamide to treat breast cancer that is node-positive and can be removed by surgery.
• Non-small cell lung cancer that is locally advanced or has metastasized. It is used:
• Alone in patients whose cancer has not gotten better after platinum chemotherapy; or
• With cisplatin in patients whose cancer cannot be treated with surgery.
• Prostate cancer that has metastasized in men whose cancer is hormone-refractory (does not respond to hormone treatment).
• Squamous cell carcinoma of the head and neck that is locally advanced. It is used with cisplatin and fluorouracil.
• Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced. It is used in patients whose disease has not been treated with chemotherapy.

A drug used with other drugs to treat prostate cancer that has spread to other parts of the body. Abiraterone acetate is used under the brand name Zytiga to treat patients whose cancer is castration resistant (has not responded to treatments that lower testosterone levels) or whose cancer is high risk and castration sensitive (has responded to treatments that lower testosterone levels). It is also used under the brand name Yonsa to treat patients whose cancer is castration resistant. Abiraterone acetate is also being studied in the treatment of other types of cancer. It lowers the amount of androgens (male hormones), such as testosterone, made by the body. This may stop the growth of cancer cells that need androgens to grow. Abiraterone acetate is a type of antiandrogen. US Brand Name(s): Yonsa Zytiga. FDA Approved: Yes

Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It should either be used following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is taken by mouth.

Abiraterone acetate is approved to be used with prednisone to treat:

• Prostate cancer that has metastasized (spread to other parts of the body). It is used:
• In patients whose cancer is castrate resistant (has not responded to treatments that lower testosterone levels). This use is approved for the Zytiga brand name of abiraterone acetate.
• With methylprednisolone in patients whose cancer is castrate resistant. This use is approved for the Yonsa brand name of abiraterone acetate.
• In patients whose cancer is high-risk and castrate sensitive (has responded to treatments that lower testosterone levels). This use is approved for the Zytiga brand name of abiraterone acetate.
• Abiraterone is also being studied in the treatment of other types of cancer.

Are you looking for or in search of FDA approved Letrozole tablets in India? Medicant Healthcare a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast cancer treatment. Need Access of Letrozole tablets, get in touch with our healthcare professional.

Femara is an aromatase inhibitor indicated for:

• Adjuva nt treatment of postmenopausal women with hormone receptor positive early brea st cancer
• Extended adjuvant treatment of postmenopausal women with early brea st cancer who have received prior standard adju vant ta moxifen thera py
• First a nd second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer

DOSAGE AND ADMINISTRATION

• Femara tablets are taken orally without regard to meals
• Recommended dose: 2.5.mg once daily

A drug used alone or with other drugs to treat AIDS-related Kaposi sarcoma, advanced ovarian cancer, and certain types of breast cancer and non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Paclitaxel stops cancer cells from growing and dividing and may kill them. It is a type of taxane.

Paclitaxel (PTX), sold under the brand name Taxol among others, is a chemotherapy medication used to treat a number of types of cancer. This includes ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi’s sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection. There is also an albumin-bound formulation.

Paclitaxel is approved to be used alone or with other drugs to treat:

AIDS-related Kaposi sarcoma. It is used as second-line therapy.

Breast cancer. It is used:

• Non-small cell lung cancer. It is used with cisplatin as first-line therapy in patients whose disease cannot be treated with surgery or radiation therapy.
• Ovarian cancer that is advanced. It is used with cisplatin as first-line therapy or alone in patients who have already received other treatment.

FDA Approves Capecitabine, First Oral Chemotherapy for the Treatment of Metastatic Colorectal Cancer. The US Food and Drug Administration (FDA) has approved capecitabine (Xeloda), the first oral chemotherapy for the treatment of metastatic colorectal cancer (the second leading cause of cancer mortality among Americans).

The FDA has approved the first generic formulation of capecitabine (Xeloda), an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer (mCRC) and metastatic breast cancer (MBC). XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for:

• Adjuv ant Colon Cancer
• Metastatic Colorectal Cancer
• Metastatic Breast Cancer

A drug that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to treat different types of cancer. Durvalumab is used alone or with other drugs to treat adults with certain types of extensive-stage small cell lung cancer or stage III non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Durvalumab may block PD-L1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Imfinzi. US Brand Name(s): Imfinzi. FDA Approved: Yes

Durvalumab is approved to treat:

• Non-small cell lung cancer (NSCLC). It is used in adults with stage III NSCLC that cannot be removed by surgery and did not get worse after platinum chemotherapy and radiation therapy.
• Small cell lung cancer in adults. It is used with etoposide phosphate and either carboplatin or cisplatin as the first treatment in adults with extensive-stage cancer.
• Durvalumab is also being studied in the treatment of other types of cancer.

The US Food and Drug Administration (FDA) has approved durvalumab for certain types of bladder and lung cancer:

• Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
• Adults with unresectable, Stage III non-small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
• In combination with etoposide and either carboplatin or cisplatin, as first-line treatment for adults with extensive-stage small cell lung cancer.

Vasopressin injection is used to control the frequent urination, increased thirst, and loss of water caused by diabetes insipidus. This is a condition that causes the body to lose too much water and become dehydrated. Vasopressin injection is also used to prevent and treat abdominal or stomach distension that occurs after surgery. It is also used in abdominal or stomach roentgenography.

Human vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized from the AVP gene as a peptide prohormone in neurons in the hypothalamus, and is converted to AVP. It then travels down the axon terminating in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). AVP has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, AVP constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.

FDA expands ribociclib indication in HR-positive, HER2-negative advanced or metastatic breast cancer. On July 18, 2018, the Food and Drug Administration expanded the indication for ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

The Kisqali Femara Co-Pack is a prescription that contains two medications, ribociclib (Kisqali) and letrozole (Femara), used as a first-line treatment for adults who have advanced or metastatic hormone-receptor-positive human epidermal growth factor-2 receptors (HER2)-negative breast cancer.1 Metastatic cancer is cancer that has spread from the primary site to other areas of the body.

• Generic Name: Ribociclib and letrozole
• Brand Name(s): Kisqali Femara Co-Pack
• Drug Availability: Prescription
• Administration Route: Oral
• Therapeutic Classification: CDK4/6 inhibitor and aromatase inhibitor
• Available Generically: No
• Active Ingredient: Ribociclib and letrozole
• Dosage Form(s): Tablet

This medication is used to treat plaque psoriasis and psoriatic arthritis. Guselkumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural substance in your body (interleukin-23) that may cause inflammation and swelling. Guselkumab can help lessen the red, scaly, itchy patches of skin caused by plaque psoriasis and lessen the pain and swelling in the joints caused by psoriatic arthritis.

Guselkumab is indicated to treat moderate to severe plaque psoriasis, and psoriatic arthritis in adults. Guselkumab is provided as a subcutaneous injection of 100 mg given every eight weeks (except for the second dose, which is given four weeks after the first dose).Guselkumab injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. It is also used alone or in combination with other medications to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults. Guselkumab injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)

This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.

This medication is used to treat certain bowel disorders (ulcerative colitis, Crohn’s disease). In these conditions, the body’s defense system (immune system) attacks healthy tissues in the gut, causing symptoms such as abdominal pain, blood in the stool, and diarrhea. Vedolizumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking the actions of a certain natural substance (integrin) in the body. This helps to decrease swelling (inflammation) in the gut, which lessens symptoms and may slow or stop damage from these bowel disorders. Vedolizumab Solution, Reconstituted (Recon Soln) –

edolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn’s disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer’s patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.

lcerative colitis and Crohn’s disease

Vedolizumab has been approved for use in adults with moderate to severe ulcerative colitis or Crohn’s disease having a poor response to tumor necrosis factor (TNF) blockers or corticosteroids, or for those who are steroid-dependent.

Checkpoint inhibitor colitis

Vedolizumab may be used to treat steroid refractory checkpoint inhibitor induced colitis, if infliximab is ineffective or contraindicated.

On January 28, 2016, the U. S. Food and Drug Administration approved eribulin (HALAVEN injection, Eisai Co., Ltd.) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

HALAVEN is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting .

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used to treat certain skin disorders (such as plaque-type psoriasis, hidradenitis suppurativa). It works by blocking a protein (tumor necrosis factor or TNF) found in the body’s immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. Adalimumab is also used to treat certain bowel conditions (Crohn’s disease, ulcerative colitis) and a certain eye disease (uveitis). Adalimumab Syringe Kit – GENERIC NAME: ADALIMUMAB

Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It is administered by injection under the skin.

Adalimumab is a disease-modifying antirheumatic drug (DMARD) and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).

Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization’s List of Essential Medicines. It is available as a biosimilar medication. In 2019, it was the 152nd most commonly prescribed medication in the United States, with more than 4 million prescriptions.